Dupilumab
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Dupilumab: From an Unspecified Approved Indication to Bronchitis
One-Sentence Summary
Dupilumab is an IL-4 receptor alpha blocker marketed in the US as Dupixent. The supplied record does not list its approved indications. The TxGNN model predicts it may be effective for bronchitis, but the direct evidence is thin. There is 1 indirect clinical trial (chronic rhinosinusitis, not bronchitis) and 6 publications drawn mostly from asthma, COPD and a review of eosinophilic plastic bronchitis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the supplied record |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 5 license records (all under one BLA, BLA761055) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
The DrugBank mechanism-of-action field is empty in the supplied data. From the prediction rationale, dupilumab blocks IL-4Rα, which shuts down both IL-4 and IL-13 signaling and dampens type 2 inflammation. Type 2 inflammation drives eosinophilic airway disease such as asthma.
Bronchitis is an airway inflammatory condition, so the link is plausible for eosinophilic or type 2-driven bronchial disease. Examples are asthma-overlap phenotypes and eosinophilic plastic bronchitis. The evidence comes from asthma and COPD data and a review of eosinophilic plastic bronchitis, so it is indirect. No study tests dupilumab in bronchitis itself.
The rationale does not hold for acute or infectious bronchitis, which has no clear type 2 mechanism. The prediction should therefore not be read as applying to bronchitis in general.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04362501 | Phase 2 | Completed | 33 | Randomized, double-blind, placebo-controlled study of dupilumab in chronic rhinosinusitis without nasal polyps. It is an upper-airway type 2 disease, not a bronchitis population, so it gives only indirect support. No results were included in the supplied data. |
No registered trial in the supplied data enrolls patients with bronchitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30273510 | 2019 | Systematic review / meta-analysis of RCTs | J Asthma | Pooled efficacy and safety of dupilumab versus placebo in uncontrolled asthma. Asthma evidence, not bronchitis. |
| 34597534 | 2022 | Open-label extension (TRAVERSE) | Lancet Respir Med | Long-term safety and efficacy of dupilumab in moderate-to-severe asthma beyond 1 year. |
| 32428511 | 2020 | Cohort / imaging study | Chest | Anti-T2 biologics, including dupilumab, and lung ventilation on MRI in prednisone-dependent asthma. |
| 39904363 | 2025 | Review | Tuberc Respir Dis | Pharmacologic options for preventing COPD exacerbations, including newer biologic agents. |
| 30196731 | 2018 | Review | Expert Opin Pharmacother | Managing asthma with smoking-induced airway disease (chronic bronchitis, emphysema, asthma-COPD overlap). These patients are excluded from most trials. |
| 38488768 | 2024 | Review | Pediatr Pulmonol | Novel therapies for eosinophilic pediatric plastic bronchitis. No abstract was supplied, so the findings are unconfirmed. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA761055 | Dupixent (sanofi-aventis U.S. LLC) | Injection, solution | Not specified in the supplied record |
The supplied record contains five identical license entries under BLA761055. They are shown here once.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: No trial or publication studies dupilumab in bronchitis. The support is indirect and comes from asthma, COPD and a review of eosinophilic plastic bronchitis. The model score is very high, but it is not backed by bronchitis-specific evidence.
To proceed, the following is needed:
- Define the target bronchitis subtype, such as an eosinophilic or type 2 phenotype, and exclude acute or infectious bronchitis
- Bronchitis-specific clinical data, or a trial in that phenotype
- The current US approved indications and the package insert warnings and contraindications
- Detailed mechanism-of-action data from DrugBank
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.